Coherus Oncology's Earnings Narrative Evolves Around Clinical Catalysts and Valuation Risks

Coherus Oncology's (CHRS) fair value is anchored at $6.75 despite a bullish initiation from Oppenheimer with an Outperform rating. Analysts are split on the outlook, with some questioning the robustness of the fair value if execution around trials, partnerships, or commercialization does not track to plan. The company completed a follow-on equity offering and filed for additional equity offerings, with multiple securities subject to lock-up agreements.